SUNY

Award-Winning Author Xue Mo to Present at the 2024 Los Angeles Times Festival of Books

Retrieved on: 
Tuesday, April 9, 2024
Peking University, SUNY, London Book Fair, Anxiety, Kingdom, Publication, Civilization, Love, Booth, Literature, Entertainment

AURORA, Ill., April 9, 2024 /PRNewswire/ -- On April 20-21, 2024, award-winning author Xue Mo will showcase his latest work, "Curses of the Kingdom of Xixia," at the 2024 Los Angeles Times Festival of Books.

Key Points: 
  • AURORA, Ill., April 9, 2024 /PRNewswire/ -- On April 20-21, 2024, award-winning author Xue Mo will showcase his latest work, "Curses of the Kingdom of Xixia," at the 2024 Los Angeles Times Festival of Books.
  • It challenges us to confront our fears and beliefs and offers a way to transcend suffering through love and faith."
  • He further questioned, "With Europe's advanced publishing industry, why hasn't it been able to address human conflict, moral decline, or anxiety?
  • Describing his creative process for "Curses of the Kingdom of Xixia," Xue Mo shared that he engaged in a spontaneous, burst-like writing style, driven by continuous flows of thought and inspiration.

The Masterpiece of Acclaimed Author Xue Mo Has Been Nominated For The Prestigious Forward Indie Award

Retrieved on: 
Tuesday, April 9, 2024
Librarian, SUNY, Attention, Face, Silver, Independent, Gold, Thelma & Louise, Hope, Kingdom, Publication, Dream, Courage

"Curses of the Kingdom of Xixia" stands as one of Xue Mo's seminal works.

Key Points: 
  • "Curses of the Kingdom of Xixia" stands as one of Xue Mo's seminal works.
  • Furthermore, in March 2023, the Independent Press Award officially announced that Xue Mo's English novella "Into the Desert" was awarded the 2024 Independent Press Award.
  • It is worth noting that Howard Goldblatt and Sylvia Li-chun Lin alone have translated nearly ten works by Xue Mo.
  • In an email, they expressed their admiration for Xue Mo and his works, stating, "Xue Mo's novels are filled with humanistic concerns and philosophical reflections.

Avangrid Foundation Provides $100,000 Grant to Expand Food Pantry at SUNY Broome

Retrieved on: 
Thursday, March 21, 2024
Other Energy, Utilities, Oil, Gas, Energy, University, Philanthropy, Education, Foundation, Health, SUNY, Avangrid, RG&E, Partnership, SUNY Broome Community College, School, Food, Clothing, Food security, Volunteering, Student, Woman, Hygiene, AGR, RG

The Avangrid Foundation, the primary philanthropic arm of leading sustainable energy company Avangrid, Inc. (NYSE: AGR), joined SUNY Broome today to celebrate the grand reopening of the college’s Hornet Hope Center, a newly upgraded on-campus food pantry and clothing closet.

Key Points: 
  • The Avangrid Foundation, the primary philanthropic arm of leading sustainable energy company Avangrid, Inc. (NYSE: AGR), joined SUNY Broome today to celebrate the grand reopening of the college’s Hornet Hope Center, a newly upgraded on-campus food pantry and clothing closet.
  • This new student resource center was made possible thanks to a $100,000 grant from the Avangrid Foundation, continuing the Foundation’s commitment to supporting food security.
  • The Avangrid Foundation grant allowed the Center to move to a larger, newly renovated space on campus with energy-efficient lighting.
  • SUNY Broome is proud to partner with Community Hunger Outreach Warehouse (CHOW) , a network of food pantries in Broome County, to assist in stocking the food pantry, open to students during regular daytime hours and by appointment.

Jimmy's Jazz & Blues Club Features GRAMMY® Award Nominee & Internationally Acclaimed Jazz Singer CYRILLE AIMEE on Sunday April 21 at 7:30 P.M.

Retrieved on: 
Tuesday, March 26, 2024
Online, SUNY, Taste, Music, Star Academy, Ticketmaster, Human, Gig, Calendar, Move On, The New York Times, Creativity, American School, Montreux Jazz Festival, Marry Me a Little, NEA Jazz Masters, Jazz, The Wall Street Journal, Singing, Apollo Theatre, Nightclub

PORTSMOUTH, N.H., March 26, 2024 /PRNewswire/ -- Jimmy's Jazz & Blues Club Features GRAMMY® Award Nominee & Internationally Acclaimed Jazz Singer CYRILLE AIMEE on Sunday April 21 at 7:30 P.M. For Cyrille Aimee improvisation is not just a technique but a way of life, one that has allowed her to share her engaging voice and sparkling creativity with the world.

Key Points: 
  • GRAMMY® Nominated Jazz Vocalist CYRILLE AIMEE has been hailed as, "a rising star in the galaxy of jazz singers" by the NEW YORK TIMES.
  • PORTSMOUTH, N.H., March 26, 2024 /PRNewswire/ -- Jimmy's Jazz & Blues Club Features GRAMMY® Award Nominee & Internationally Acclaimed Jazz Singer CYRILLE AIMEE on Sunday April 21 at 7:30 P.M. For Cyrille Aimee improvisation is not just a technique but a way of life, one that has allowed her to share her engaging voice and sparkling creativity with the world.
  • To date, Aimee has released 14 acclaimed albums, including 2019's album Move On featuring cover versions of songs by Stephen Sondheim .
  • Tickets for CYRILLE AIMEE at Jimmy's Jazz & Blues Club on Sunday April 21 at 7:30 P.M., as well as the current list of 2024 shows, can be found on Ticketmaster and Jimmy's Online Event Calendar at: http://www.jimmysoncongress.com/events.

The World Needs Don Quixote-Style Writers: "Curses of the Kingdom of Xixia" Written by Acclaimed Author Xue Mo Successfully Launched at the 2024 London Book Fair

Retrieved on: 
Tuesday, March 19, 2024
SUNY, University at Albany, SUNY, International, London Book Fair, Frankfurt Book Fair, Anxiety, Kingdom, Love, Violence

AURORA, Ill., March 19, 2024 /PRNewswire/ -- New Fiction titled "Curses of the Kingdom of Xixia" written by Xue Mo was launched at the London Book Fair.

Key Points: 
  • AURORA, Ill., March 19, 2024 /PRNewswire/ -- New Fiction titled "Curses of the Kingdom of Xixia" written by Xue Mo was launched at the London Book Fair.
  • Neyko Genchev, President of Faber Publishers and Deputy Mayor of Sofia, Bulgaria, also dropped by to congratulate Mr. Xue Mo on his new publication.
  • Genchev, who has been following Xue Mo's work since encountering it at the Beijing International Book Fair (BIBF), regards "Select Stories by Xue Mo" as his bedside reading.
  • He said that Xue Mo is a rare embodiment of thousands of years of Chinese sages.

Campaign to Repeal New York's Multibillion Dollar Stock Transfer Tax Rebate Takes Aim at Governor Hochul, Legislators and Corporate Naysayers

Retrieved on: 
Tuesday, March 12, 2024
Transfer, Homelessness, SUNY, Letter, Assembly, Sanitation, Tax, STT, Education, CBC, Common, School, Political campaign staff, Sleep, STTR, Security, Sale, Transport, Student, Crime, CUNY, Housing, NYS, New Yorker, Campaign, Cat, Book, Firefighter, DSM-IV codes, Coalition for the Homeless, Sadness, Senate, State, Legislation, Police, Cryptocurrency

Their responses will be tabulated and reported on the Campaign's website GreedvsNeed.org describing if they "Support Greed" or "Support Need."

Key Points: 
  • Their responses will be tabulated and reported on the Campaign's website GreedvsNeed.org describing if they "Support Greed" or "Support Need."
  • Nonresponders will be tabulated as supporting greed and will be publicly admonished and become the focus of the statewide Greed V$ Need Campaign.
  • From 1905 to 1981, New York State collected a tiny one-tenth of one percent tax called the Stock Transfer Tax (STT) on the sale of corporate stocks.
  • Some leading legislators are saying, "Now is not the right time to repeal the STTR."

StrainsForPains, Inc. Discusses Inspiration, App Technology and CBD Market Entrance with The Stock Day Podcast

Retrieved on: 
Thursday, February 29, 2024
Pet, Anxiety, Parkinson's disease, Intelligence, Traction, Chemical oxygen demand, DSM-IV codes, Quality of life, Cancer, MIT, Pain, OTC Markets Group, State, Database, Cannabinoid, State university system, International Cannabinoid Research Society, Chronic pain, Business, SUNY, Depression, CBD, Patient, Medicine, Osteoarthritis, Pharmacotherapy, Movement, Interview, Insomnia, Cannabis, Research, Alzheimer's disease

I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.

Key Points: 
  • I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.
  • I developed regenerative medicine systems with stem cell technology in the 1980's working on umbilical cord therapy to treat genetic diseases, cancers, and inherited disorders.
  • In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products.
  • We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app.

AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

Retrieved on: 
Wednesday, February 28, 2024
Research, Doctor of Philosophy, General partnership, Drug development, Growth, Frustration, University, Chronic pain, SUNY, Biomedical sciences, Epilepsy, Neurology, Rett syndrome, Smith, Kline & French, Acadia Pharmaceuticals, School, University at Buffalo, Biotechnology, ATyr Pharma, Health, Neurotoxicity, Cell, Therapy, DSM-IV codes, Brain, Neuropharmacology, Proteostasis, Amathus, Record, Drug discovery, Peripheral neuropathy, MPS, Physics, OPKO Health, Genomics, Acquisition, EMD, LoDo, Denver, MD, Organoid, Multiple sclerosis, Prevalence, Brown University, Brandeis University, Serono, Patient, Disease, GSK plc, Pharmaceutical industry

Dr. Pfost noted, “AxoSim embodies the entrepreneur’s sweet spot--when market need, technological innovation, timing and team all align. The growing prevalence of neurological diseases places enormous burdens on patients, their families and society. Yet despite billions in investment, neurology R&D continues to disappoint. AxoSim’s transformational approach addresses a key contributor to these failures—the lack of relevant disease models—by providing functional human data from its microphysiological system (MPS) organoid technologies early in the process. AxoSim aims to become an industry leader in helping to deliver urgently needed new drugs and I welcome the opportunity to contribute to its success.”

Key Points: 
  • Dr. Pfost and Dr. Weiner have decades of experience in building successful biotechnology companies spanning therapeutics, diagnostics and life science tools and technologies.
  • “Our recent acquisition of a third platform technology positions AxoSim for growth, and we are fortunate to have these two talented industry veterans assuming key leadership roles,” said Lowry Curley, PhD, co-founder and Chief Executive Officer of AxoSim.
  • “Dale and Dave bring successful track records in building life sciences businesses, with broad and complementary skill sets.
  • Dale’s work in life science tools and venture finance is highly relevant, as is Dave’s expertise in leading neurological drug discovery and clinical development.

RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance on Development of First-in-Class Agent Focused on Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, February 21, 2024
TEC, IPF, University, Idiopathic disease, Division, Assistant, Critical care, Idiopathic pulmonary fibrosis, Chronic obstructive pulmonary disease, Clinical research, Outline of health sciences, Consultant, Respiratory Medicine, Death, SUNY, Observation, Harvard Medical School, COPD, Pharmaceutical industry

CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).

Key Points: 
  • CUMBERLAND, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce the formation of its Therapeutic Expert Council (TEC).
  • The TEC will help guide the development of RS BioTherapeutics’ first-in-class, steroid-free agent, RSBT-001, in development for Chronic Obstructive Pulmonary Disease (COPD), the third leading cause of death in the world; and Idiopathic Pulmonary Fibrosis (IPF), a rare disease with no cure that claims 40,000 lives each year in the U.S.
  • All have exceptional credentials and are uniquely qualified to help support the development of our first investigational compound, RSBT-001.
  • I’m excited to collaborate with them and look forward to engaging their diverse perspectives spanning the fields of COPD, IPF, and other diseases characterized by pulmonary inflammation.”

GlobalFoundries and Biden-Harris Administration Announce CHIPS and Science Act Funding for Essential Chip Manufacturing

Retrieved on: 
Monday, February 19, 2024
CHIPS, General Motors, Research, GameChanger, Empire, Education, Investment, News, Upstate, Growth, Commerce, Qualcomm, University, ITC, SUNY, Lockheed Martin, Energy, Century, Semiconductor, Workforce, Student, GlobalFoundries, Electronics, GM, White, Economic development, AMD, Ecosystem, HVCC, Partnership, Hudson Valley Community College, Learning, Economy, NYPA, Gallium nitride, Capital, Chair, Science, GFS, AI, Internet of things, Government, COVID-19, Lockheed, Empire State, Renewable energy

MALTA, N.Y. and ESSEX JUNCTION, Vt., Feb. 19, 2024 (GLOBE NEWSWIRE) -- The U.S. Department of Commerce today announced $1.5 billion in planned direct funding for GlobalFoundries (Nasdaq: GFS) (GF) as part of the U.S. CHIPS and Science Act. This investment will enable GF to expand and create new manufacturing capacity and capabilities to securely produce more essential chips for automotive, IoT, aerospace, defense, and other vital markets.

Key Points: 
  • This investment will enable GF to expand and create new manufacturing capacity and capabilities to securely produce more essential chips for automotive, IoT, aerospace, defense, and other vital markets.
  • GF is the first semiconductor pure play foundry to receive a major award (over $1.5 billion) from the CHIPS and Science Act, designed to strengthen American semiconductor manufacturing, supply chains and national security.
  • “When I wrote the CHIPS & Science Law, I made sure there was funding especially for the feature-rich, legacy chips that GlobalFoundries produces in Malta and that are essential for America’s auto industry and national defense.
  • “The CHIPS Act funding will help encourage innovation and expansion of this vital sector in our state and across the country.